Benchmarking spleen tyrosine kinase (Syk) expression in T- and NK-cell neoplasms: Implications for therapeutic targeting

Br J Haematol. 2025 May 13. doi: 10.1111/bjh.20151. Online ahead of print.

Authors

Affiliation

¹ Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

PMID: 40361307
DOI: 10.1111/bjh.20151

No abstract available

Keywords: Syk; T‐cell lymphoma; flow cytometry; immunohistochemistry; new drugs for lymphoma.

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States